Literature DB >> 22708291

[Parvovirus B19 DNA testing in Polish blood donors, 2004-2010].

Piotr Grabarczyk1, Jolanta Korzeniowska, Grzegorz Liszewski, Aleksandra Kalińska, Ewa Sulkowska, Maria Krug-Janiak, Aneta Kopacz, Magdalena Łetowska, Ewa Brojer.   

Abstract

UNLABELLED: Since 2004 Polish blood donors have been tested for parvovirus B19 (B19V) DNA. The screening testing has been performed in donors of plasma for fractionation and anti-D and anti-HBs production and donors of erythrocytes used for immunization. AIM is to present methods of the testing, quality control and results in period 2004-2010.
MATERIAL AND METHODS: Testing was performed in individual donation testing (IDT) in Regional Blood Transfusion Center (RBTC) in Lublin or in pools of 24 in Institute of Haematology and Transfusion Medicine in Warsaw (IHTM). Quantitative testing with real-time PCR was preceded with nucleic acid isolation on silica based methods (Prepito Viral DNA/RNA, Chemagen and QIAamp DNA Mini Kit, QIAGEN). Amplification was performed initially with home made method and later with commercial assay (Artus Parvo B19 RG PCR Kit on Rotor Gene 6 000). In total 17 625 donations were tested: 8 539 in pools and 9 090 individually. Beside routine external quality control programmes in which both laboratories participated (Proficiency Study VQC,Amsterdam, Holand; EQA Programe, Glasgow, Scotland), panel containing negative samples, positive with very high DNA B 19V level and plasma infected with genotype 2 was prepared for RBTC in Lublin.
RESULTS: B19V infection frequency was 1:980 donations, low viraemic donations were detected most frequently (1:1 037). It was identified only one donation with DNA load that could cause potential health risk for plasma product recipients (1:17 625). In one of the donors B 19V DNA was observed for 3 years and 3 months. In acute or persistent phase of infection no clinical or laboratory symptoms (morphology of peripheral blood, ALT) were observed. Due to risk of underestimation of viral load connected with viral genome polymorphism all donations with B19V positive result were not allowed to be clinically used.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22708291

Source DB:  PubMed          Journal:  Przegl Epidemiol        ISSN: 0033-2100


  5 in total

Review 1.  Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Gabriele Calizzani; Fabio Candura; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-04       Impact factor: 3.443

2.  Seroprevalence of antibodies to primate erythroparvovirus 1 (B19V) in Australia.

Authors:  Helen M Faddy; Elise C Gorman; Veronica C Hoad; Francesca D Frentiu; Sarah Tozer; R L P Flower
Journal:  BMC Infect Dis       Date:  2018-12-07       Impact factor: 3.090

Review 3.  Molecular and serological markers of human parvovirus B19 infection in blood donors: A systematic review and meta-analysis.

Authors:  Mohammad Farahmand; Ahmad Tavakoli; Saied Ghorbani; Seyed Hamidreza Monavari; Seyed Jalal Kiani; Sara Minaeian
Journal:  Asian J Transfus Sci       Date:  2021-11-01

4.  Prevalence and Phylogenetic Analysis of Parvovirus (B19V) among Blood Donors with Different Nationalities Residing in Qatar.

Authors:  Doua Abdelrahman; Duaa W Al-Sadeq; Maria K Smatti; Sara A Taleb; Raed O AbuOdeh; Enas S Al-Absi; Asmaa A Al-Thani; Peter V Coyle; Nader Al-Dewik; Ahmed A Al Qahtani; Hadi M Yassine; Gheyath K Nasrallah
Journal:  Viruses       Date:  2021-03-24       Impact factor: 5.048

5.  Overall prevalence of human parvovirus B19 among blood donors in mainland China: A PRISMA-compliant meta-analysis.

Authors:  Xin Li; Zheng Lin; Jiayan Liu; Yuanyuan Tang; Xiaohong Yuan; Nainong Li; Zhenxing Lin; Yuanzhong Chen; Ailin Liu
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.